Clicky

AstraZeneca PLC(ZEGA) News

Date Title
Aug 9 Solid Earnings Reflect AstraZeneca's (LON:AZN) Strength As A Business
Aug 7 Influenza Vaccine Market Research Report 2025-2030 Featuring GSK, Abbott, Pfizer, AstraZeneca, Sanofi, Moderna, CSL, Emergent BioSolutions, BIKEN, Serum Institute of India, Sinovac, GC Biopharma
Aug 7 Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) and adults with generalized myasthenia gravis (gMG)
Aug 7 RFK Jr’s mRNA funding halt signals “shift in US public health”
Aug 7 Inside AstraZeneca’s long-game strategy in lung cancer
Aug 6 IonQ Announces Second Quarter Financial Results
Aug 6 Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update
Aug 6 Compugen Reports Second Quarter 2025 Results
Aug 6 US Health Department Ending Federal mRNA Vaccine Development
Aug 6 Cancer Antibody Drug Conjugates Market Research 2025-2031 | Pfizer, AstraZeneca, and Biotechs Like Miracogen Advance Cancer ADCs with Strategic Acquisitions and Innovative Pipelines
Aug 6 Trump says pharma tariffs to start small, then soar to 250%
Aug 5 Trump threatens 250pc tariffs on drug imports
Aug 5 EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data
Aug 5 SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
Aug 4 Cellectis Reports Second Quarter 2025 Financial Results & Business Updates
Aug 4 Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Aug 4 AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval
Aug 3 Why Drug Prices for Some Big Medicines Will Remain High for a Longer Time
Aug 2 Drugmakers are pouring billions of dollars into new US manufacturing. It still won’t achieve all of Trump’s tariff goals
Aug 2 AstraZeneca Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags